Karyopharm Therapeutics

Price & Volume

Stats

52W Range	$5.90-$24.75
Market Cap	$57.9M
Shares Short	20M

Financials

Revenue (12 Mos)	$145.2M
Revenue Growth (YoY)	-9.5%
Gross Profit (12 Mos)	$139.2M
Diluted EPS	-$13.95

News

Yahoo Finance • last year

Karyopharm Shares Data at ASH 2023 Showing Strong SVR and TSS Durability Observed from Phase 1 Study of Selinexor 60mg and Ruxolitinib in JAK Inhibitor (JAKi)-Naïve Myelofibrosis Patients, with no SVR or TSS Progressions Observed As of the Data Cutoff(1)

Yahoo Finance • last year

Karyopharm to Participate at Upcoming Investor Conferences

Yahoo Finance • last year

Karyopharm Announces Clinical Trial Collaboration with Bristol Myers Squibb to Evaluate Novel CELMoD™ Agent CC- 92480 Mezigdomide in Combination with Selinexor in Patients with Relapsed/Refractory Multiple Myeloma

Yahoo Finance • 2 years ago

Karyopharm Therapeutics (KPTI) Q1 2023 Earnings Call Transcript

About

CEO	Mr. Richard A. Paulson M.B.A.
CFO	Ms. Lori A. Macomber CPA
Address	85 Wells Avenue, Newton, MA, United States, 02459-3298
Sector	Healthcare
Industry	Biotechnology
Full-Time Employees	279